Outcome of Community-Initiated Treatment of Drug-Resistant Tuberculosis Patients in Akwa Ibom State, Nigeria

Download Article

DOI: 10.21522/TIJAR.2014.SE.22.02.Art011

Authors : Asuquo, E. A.

Abstract:

Drug-resistant Tuberculosis (DRTB) occurs when the drugs used to treat TB are misused or mismanaged by, WHO 2018 Examples of misuse or mismanagement include People who do not complete a full course of TB treatment, Health care providers prescribing the wrong treatment (the wrong dose or length of time), Drugs for proper treatment are not available, and poor quality of drugs. The study aimed at determining the treatment outcome of Community-Initiated Drug-Resistant Tuberculosis Patients registered between January 2017 and December 2020.in Akwa Ibom State, Nigeria. The study design was a retrospective cohort study; a total sampling technique was employed to review patients that were diagnosed and registered during the period of study. The demographic and clinical data of each patient were retrieved from the DR-TB patient treatment cards, DR-TB patient treatment progress notes from directly observed treatment short-course (DOTS) providers in the community, the state DR-TB central register, and treatment card. Data were analyzed using Statistical Package for Social Sciences (SPSS) Software (Version 23; SPSS, Chicago, IL, USA). The median age of clients that participated in the study was 34 years [27- 49.5]. Most of the participants were male (56.2%), and a greater proportion of the enrollees were all new cases (76.3%). The study determined some of the sociodemographic characteristics of patients that received treatment for drug-resistant tuberculosis using the Community-Initiated model, their health outcomes, and assessed the predictors of some of the health outcomes.

References:

[1] Lauge C, Chesor D, Heyckendof J, Leung CC, Udoradie Z, Dhede K., 2018, Drug-resistant tuberculosis; an uptake on disease burden, diagnose and treatment Respirology 23(7);656-673, https://pubmed.ncbi.nlm.nih.gov/29641838/.

[2] World Health Organization. (2021). Tuberculosis. Available from: https://www.who.int/fact-sheet/details/tuberculosis/ Accessed on the 3rd of November 2021.

[3] World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2018. Available from:  https://apps.who.int/iris/handle/10665/274453.

[4] WHO global TB report 2017; general, world health organization: who, int’l team global tuberculosis program. Available from www.who.int. Accessed on the 12th of November 2021.

[5] World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2019, Available from: https://www.who.int/publications/i/item/9789241565714.

[6] Monno L, Angarano G, Carbonara S, Coppola S, Costa D, Quanl M et al., 1991, Emergency of drug-resistant mycobacterium tuberculosis in HIV infected patient, Lancet .337(8745-852), https://dx.doi.org/10.1155%2F2007%2F986794.

[7] Safaev K, Parpieva N, Liverko I, Yuldashev S, Dumchev K, Gadoev J, Korotych O, Harries AD. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. Int J Environ Res Public Health. 2021 Apr 27;18(9):4663. doi: 10.3390/ijerph18094663. PMID: 33925705; PMCID: PMC8124452 https://pubmed.ncbi.nlm.nih.gov/33925705/.

[8] Akwa Ibom State History. http://www.encyclopedia.com/doc/1G2-2870600010.html.

[9] Oyefabi A, Adelekan B, Adetisa E, Emmanuel L, Jimoh O., 2020, Prediction of intensive phase treatment outcome among patients with multi-drug resistant tuberculosis in Zaria- North-western Nigeria. Journal of community medicine and primary health care.32(2),95-107. https://doi.org/10.4314/jcmphc.v32i2.8.

[10] Bajehson M, Musa B. M, Gidado M, Nsa B, Sari U, Itabibu A.T, Jijjani IA, et al.,2019, Determinants of mortality among patients with drug resistance tuberculosis in northern Nigeria, plosora Plos One Journal, 14(11), e0225165, https://doi.org/10.1371/journal.pone.0225165.

[11] Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119–28, https://doi.org/10.1056/nejmoa022928.

[12] Getacher T, Bayray A, Weldearegay B (2013) Survival and prediction of mortality among patient under multi_drug resistant tuberculosis treatment in Ethiopia, St Peter’s specialize tuberculosis hospital, Ethiopia. Internal Journal of pharmaceutical science and research 4(2),776. https://www.researchgate.net/profile/Theodros-Zemedu/publication/263086889.

[13] Heller T, Lessells R. J, Wallrauch C. G, Barnighausen T, Cook Gs, Nhlongo L, et al., 2010, Community-based treatment for multidrug-resistant tuberculosis in rural Kirazulu-natal, South Africa. The International Journal of Tuberculosis and Live Disease 14(14), 420-426, https://pubmed.ncbi.nlm.nih.gov/20202299/.

[14] Mibei DJ, Kiarie JW, Wairia A, Kamene M, Okumu ME. Treatment outcomes of drug-resistant tuberculosis patients in Kenya. Int J Tuberc Lung Dis. 2016 Nov;20(11):1477-1482. Doi: 10.5588/ijtld.15.0915. PMID: 27776588. https://pubmed.ncbi.nlm.nih.gov/27776588/.